Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia.

Takeshi OsonoiShinichiro ShirabeMiyoko SaitoMitsuru HosoyaNorie WatahikiSatako DouguchiKensuke OfuchiMakoto Katoh

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2023)

These findings suggest that a 12-week course of dapagliflozin causes an increase in hemoglobin levels due to its hematopoietic effects in elderly type 2 diabetics with renal impairment, but that these effects may be independent of body water loss and iron metabolism improvement.

Keyphrases

iron deficiency
bone marrow
middle aged
adipose tissue
study protocol
insulin resistance
red blood cell